Eicosapentaenoic Acid
New STRENGTH analysis puts spotlight on CV impact of omega-3 fatty acids
Higher blood levels of eicosapentaenoic acid 1 year after daily omega-3 carboxylic acid supplementation were not associated with lower CV risk, according to a secondary analysis of the STRENGTH trial.
CV benefits of icosapent ethyl may increase as daily EPA levels increase
Improvements in CV outcomes from hypertriglyceridemia treatment with icosapent ethyl, compared with placebo, increased as daily levels of eicosapentaenoic acid increased, according to an analysis of the REDUCE-IT trial.
Omega-3 fatty acid supplementation may reduce risk for certain CVD outcomes
Supplementation with eicosapentaenoic acid and docosahexaenoic acid may reduce the risk for some CVD outcomes, including fatal MI and CHD events, researchers found.
FDA approves CV event risk reduction indication for icosapent ethyl
Top stories in cardiology: FDA warns about biotin, insomnia symptoms increase CVD risk
Omega-3 fatty acids with statin therapy reduce major adverse CV events
Eicosapentaenoic acid, or EPA, combined with statin therapy significantly reduced the incidence of major adverse CV events, according to a meta-analysis published in The American Journal of Cardiology.
Icosapent ethyl appropriate to use to reduce CV risk, despite pending questions
CHICAGO — Findings of cardiovascular benefit with icosapent ethyl treatment from the REDUCE-IT trial have already revealed actionable clinical implications, but determining whether triglyceride reductions or eicosapentaenoic acid increases are the key mechanisms will be the focus of continuing research, according to a speaker at the Cardiometabolic Heath Congress.